Standard BioTools Inc. (LAB)
NASDAQ: LAB · Real-Time Price · USD
1.630
-0.030 (-1.81%)
At close: Dec 19, 2025, 4:00 PM EST
1.650
+0.020 (1.23%)
After-hours: Dec 19, 2025, 7:50 PM EST
Standard BioTools Revenue
Standard BioTools had revenue of $19.55M in the quarter ending September 30, 2025, a decrease of -11.47%. This brings the company's revenue in the last twelve months to $128.83M, up 8.89% year-over-year. In the year 2024, Standard BioTools had annual revenue of $174.43M with 64.03% growth.
Revenue (ttm)
$128.83M
Revenue Growth
+8.89%
P/S Ratio
3.64
Revenue / Employee
$207,502
Employees
818
Market Cap
626.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 174.43M | 68.09M | 64.03% |
| Dec 31, 2023 | 106.34M | 8.39M | 8.57% |
| Dec 31, 2022 | 97.95M | -32.63M | -24.99% |
| Dec 31, 2021 | 130.58M | -7.56M | -5.47% |
| Dec 31, 2020 | 138.14M | 20.90M | 17.83% |
| Dec 31, 2019 | 117.24M | 4.28M | 3.79% |
| Dec 31, 2018 | 112.96M | 11.03M | 10.82% |
| Dec 31, 2017 | 101.94M | -2.51M | -2.40% |
| Dec 31, 2016 | 104.45M | -10.27M | -8.95% |
| Dec 31, 2015 | 114.71M | -1.74M | -1.50% |
| Dec 31, 2014 | 116.46M | 45.27M | 63.60% |
| Dec 31, 2013 | 71.18M | 18.85M | 36.02% |
| Dec 31, 2012 | 52.33M | 9.47M | 22.09% |
| Dec 31, 2011 | 42.87M | 9.31M | 27.73% |
| Dec 31, 2010 | 33.56M | 8.15M | 32.06% |
| Dec 31, 2009 | 25.41M | 10.07M | 65.58% |
| Dec 27, 2008 | 15.35M | 8.07M | 110.96% |
| Dec 29, 2007 | 7.28M | 877.00K | 13.71% |
| Dec 31, 2006 | 6.40M | -1.28M | -16.63% |
| Dec 31, 2005 | 7.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LAB News
- 4 weeks ago - Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry - Business Wire
- 5 weeks ago - Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks - PRNewsWire
- 6 weeks ago - Standard BioTools Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025 - GlobeNewsWire
- 3 months ago - Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development - PRNewsWire
- 4 months ago - Standard BioTools Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study - GlobeNewsWire
- 5 months ago - Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025 - GlobeNewsWire